Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-98, 2002. ,
DOI : 10.1056/NEJMoa011954
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.26, issue.21, pp.3543-3551, 2008. ,
DOI : 10.1200/JCO.2007.15.0375
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res, vol.58, pp.4349-4357, 1998. ,
Comparison of the cellular pharmacokinetics and toxicity of 2?, 2?-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine, Cancer Res, vol.48, pp.4024-4031, 1988. ,
Action of 2?, 2?-difluorodeoxycytidine on DNA synthesis, Cancer Res, vol.51, pp.6110-6117, 1991. ,
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2?, Mol Pharmacol, vol.38, pp.2-567, 1990. ,
Gemcitabine: metabolism, mechanisms of action, and self-potentiation, Semin Oncol, vol.22, issue.4, pp.3-10, 1995. ,
Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro, Exp Hematol, vol.26, pp.421-425, 1998. ,
Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics, Clinical Cancer Research, vol.12, issue.6, pp.1794-1803, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1969
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial, British Journal of Cancer, vol.89, issue.7, pp.1192-1199, 2003. ,
DOI : 10.1038/sj.bjc.6601283
Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976. ,
DOI : 10.1159/000180580
Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, vol.665, issue.1, pp.171-181, 1995. ,
DOI : 10.1016/0378-4347(94)00521-6
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine., Journal of Clinical Oncology, vol.9, issue.3, pp.491-498, 1991. ,
DOI : 10.1200/JCO.1991.9.3.491
Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism, Journal of Clinical Oncology, vol.25, issue.1, pp.32-42, 2007. ,
DOI : 10.1200/JCO.2006.06.7405
A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity, Pharmacogenetics, vol.13, issue.1, pp.29-38, 2003. ,
DOI : 10.1097/00008571-200301000-00005
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway, The Pharmacogenomics Journal, vol.4, issue.5, pp.307-314, 2004. ,
DOI : 10.1038/sj.tpj.6500259
Cytidine Deaminase. The 2??3 ?? Crystal Structure of an Enzyme: Transition-state Analog Complex, Journal of Molecular Biology, vol.235, issue.2, pp.635-656, 1994. ,
DOI : 10.1006/jmbi.1994.1018
Isolation and characterization of the gene coding for human cytidine deaminase, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1443, issue.3, pp.323-333, 1998. ,
DOI : 10.1016/S0167-4781(98)00235-8
Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial, Journal of Clinical Oncology, vol.18, issue.13, pp.2545-2552, 2002. ,
DOI : 10.1200/JCO.2000.18.13.2545
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer, Annals of Oncology, vol.13, issue.6, pp.919-927, 2002. ,
DOI : 10.1093/annonc/mdf164
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*, Breast Cancer Research and Treatment, vol.17, issue.4, pp.171-179, 2001. ,
DOI : 10.1023/A:1011945623464
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acue myeloid leukemia, Br J Haematol, vol.144, pp.388-394, 2008. ,
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients, Clinical Cancer Research, vol.14, issue.6, pp.1797-1803, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1364